Journal
NAR CANCER
Volume 3, Issue 3, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/narcan/zcab026
Keywords
-
Categories
Funding
- Swedish Foundations' Starting Grant (SFSG)
- StemTherapy
- Swedish Research Council (Vetenskapsradet)
- Swedish Cancer Society (Cancerfonden) [190320Pj]
- Danish Cancer Society [R167-A10943-17-S2]
- Cancerfonden Postdoctoral Fellow [190042PT]
- CONICYT postdoctoral scholarship (Becas Chile) [2018 - 74190071]
- Wenner-Gren Foundation postdoctoral scholar [UPD2019-0276]
Ask authors/readers for more resources
SCARNA15 directs alternative splicing and stress adaptation in cancer cells, impacting the expression and function of key tumor suppressors ATRX and p53.
Small Cajal body-specific RNAs (scaRNAs) guide post-transcriptional modification of spliceosomal RNA and, while commonly altered in cancer, have poorly defined roles in tumorigenesis. Here, we uncover that SCARNA15 directs alternative splicing (AS) and stress adaptation in cancer cells. Specifically, we find that SCARNA15 guides critical pseudouridylation (psi) of U2 spliceosomal RNA to fine-tune AS of distinct transcripts enriched for chromatin and transcriptional regulators in malignant cells. This critically impacts the expression and function of the key tumor suppressors ATRX and p53. Significantly, SCARNA15 loss impairs p53-mediated redox homeostasis and hampers cancer cell survival, motility and anchorage-independent growth. In sum, these findings highlight an unanticipated role for SCARNA15 and psi in directing cancer-associated splicing programs. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available